allulose glp 1 effect GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose Secretion of GLP-1 but not

Pacher, P., Btkai, S

You can listen to this great interview here, or anywhere you find podcasts

The FDA-approved prescribing information for semaglutide products does not list ibuprofen as a contraindicated medication

Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls

A seven-year study with nearly 120,000 participants found GLP-1s were associated with lower rates of new prostate cancer diagnoses in high-risk men, compared to drugs such as Merck's Propecia and GSK's Avodart, which are used to shrink enlarged prostate glands

When administered, these medications work through several mechanisms: Slowing gastric emptying - Food remains in the stomach longer, which can contribute to feelings of fullness Reducing appetite signaling - The medications act on brain regions involved in hunger and satiety Improving insulin secretion - In response to food intake, insulin release becomes more efficient, which is why these medications were originally developed for diabetes Decreasing glucagon secretion - This hormone raises blood sugar, so reducing it helps with glucose control The two primary GLP-1 receptor agonists used for weight loss are: Semaglutide - FDA-approved for weight management under the brand name Wegovy (also sold as Ozempic for diabetes and Rybelsus as an oral diabetes medication)